Literature DB >> 10234596

Morning spot and 24-hour urinary 6 beta-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP 3A4 induction.

J Q Tran1, S J Kovacs, T S McIntosh, H M Davis, D E Martin.   

Abstract

A single spot urine collection to measure the ratio of 6 beta-hydroxycortisol (6 beta-OHC) to free cortisol (C) has been proposed as a research tool for the assessment of CYP3A4 induction. However, intraindividual variability in 6 beta-OHC/C under basal conditions and conditions of induction has not been prospectively evaluated, and findings on the correlation between morning spot and 24-hour urinary ratios have been conflicting. In this study, the variability in morning spot and 24-hour urinary 6 beta-OHC/C ratios was assessed in 15 healthy adult male volunteers before, during, and after oral administration of rifampin 600 mg once daily for 14 days. In addition, the correlation between morning spot and 24-hour urinary ratios measured under baseline, maximum induction, and postinduction was determined. Intraindividual coefficients of variation (CVs) at baseline for the morning spot and 24-hour ratios were 54.3% and 57.1%, respectively, and were not changed significantly during induction. No significant differences were detected in the variability between the morning spot and 24-hour ratios at baseline, maximum induction, or postinduction. A good correlation (r = 0.61, p < 0.0001) was detected between the mean morning spot and 24-hour urinary ratios. Mean (+/- SEM) percent increases in the morning spot and 24-hour ratios at maximum induction relative to baseline were 320% +/- 73% and 137% +/- 30%, respectively (p = 0.019). All 15 subjects had an increase in the mean morning spot ratio at maximum induction relative to baseline, whereas 12 subjects showed an increase in the mean 24-hour ratio. The time course of changes in the mean morning spot urinary ratio in response to a 14-day course of rifampin was also similar to that reported previously in a study using 24-hour urine collections. These findings suggest that measurement of the morning spot urinary 6 beta-OHC/C ratio is an effective and efficient method for evaluating the potential of investigational agents to induce CYP3A4.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10234596

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  17 in total

Review 1.  Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism.

Authors:  Bertrand Rochat
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Pharmacokinetics of ruboxistaurin are significantly altered by rifampicin-mediated CYP3A4 induction.

Authors:  Kwee Poo Yeo; Stephen L Lowe; Ming Tung Lim; James R Voelker; Jennifer L Burkey; Stephen D Wise
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

3.  Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin.

Authors:  Sebastian Härtter; Michael Koenen-Bergmann; Ashish Sharma; Gerhard Nehmiz; Ute Lemke; Wolfgang Timmer; Paul A Reilly
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

4.  Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients.

Authors:  An Wang; Bang-Ning Yu; Chen-Hui Luo; Zhi-Rong Tan; Gan Zhou; Lian-Sheng Wang; Wei Zhang; Zhi Li; Jie Liu; Hong-Hao Zhou
Journal:  Eur J Clin Pharmacol       Date:  2005-01-14       Impact factor: 2.953

5.  A single dose of methadone inhibits cytochrome P-4503A activity in healthy volunteers as assessed by the urinary cortisol ratio.

Authors:  D W Boulton; P Arnaud; C L DeVane
Journal:  Br J Clin Pharmacol       Date:  2001-04       Impact factor: 4.335

6.  Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir.

Authors:  Sven Wind; Thomas Giessmann; Arvid Jungnik; Tobias Brand; Kristell Marzin; Julia Bertulis; Julia Hocke; Dietmar Gansser; Peter Stopfer
Journal:  Clin Drug Investig       Date:  2014-03       Impact factor: 2.859

Review 7.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.

Authors:  David E Martin; Robert Blum; Judy Doto; Hal Galbraith; Charles Ballow
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

9.  The effect of rosuvastatin on oestrogen & progestin pharmacokinetics in healthy women taking an oral contraceptive.

Authors:  Steven G Simonson; Paul D Martin; Mike J Warwick; Patrick D Mitchell; Dennis W Schneck
Journal:  Br J Clin Pharmacol       Date:  2004-03       Impact factor: 4.335

Review 10.  Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.

Authors:  M M Galteau; F Shamsa
Journal:  Eur J Clin Pharmacol       Date:  2003-11-06       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.